Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer.
Mohamed N OmarPier Vitale NuzzoFrancesco RaveraSara BleveGiuseppe Nicolò FanelliClaudio ZanettiniItzel ValenciaLuigi MarchionniPublished in: Journal of translational medicine (2023)
We introduce a robust gene signature to predict pathological complete response (pCR) in patients with TNBC. This signature applies easily interpretable, rank-based decision rules to genes regulated by the Notch signaling pathway, a known determinant in breast cancer chemoresistance. The robust predictive and prognostic performance of the signature make it a strong candidate for clinical implementation, aiding in the stratification of TNBC patients undergoing NACT.
Keyphrases
- neoadjuvant chemotherapy
- genome wide
- patients undergoing
- signaling pathway
- genome wide identification
- locally advanced
- cell proliferation
- copy number
- healthcare
- sentinel lymph node
- epithelial mesenchymal transition
- gene expression
- pi k akt
- genome wide analysis
- transcription factor
- quality improvement
- oxidative stress
- young adults
- breast cancer risk